Gynecologic Cancer 3005/ABBVIE M13-694

April 26, 2017

Sponsor: Gynecologic Oncology Group

Number: 3005/ABBVIE M13-694

The focus of this study is to evaluate the efficacy, safety, and tolerability of Veliparib in women with previously untreated, Stage III or IV (cancer which has spread from the site of the primary (original) tumor only to surrounding tissue, lymph nodes, or the development of secondary malignant growths at a distance from a primary site of cancer), high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Who’s eligible:

  • The patient must have a histologic (tissue microscopically examined) diagnosis of International Federation of Gynecology and Obstetrics (FIGO), Stage III or IV (cancer which has spread from the site of the primary (original) tumor only to surrounding tissue, lymph nodes, or the development of secondary malignant growths at a distance from a primary site of cancer), epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
  • The patient must have appropriate tissue available for histologic evaluation. There must be high-grade serous adenocarcinoma.
  • The patient must be willing to undergo testing for gBRCA (tumor suppressor genes, or antioncogenes).
  • The patient must have adequate hematologic, renal, and hepatic function.
  • This study is for women age 18 and older.

Available at: The Hospital of Central Connecticut.

Cancer Clinical Research Office